Real-world Study of UTD1 in Chinese Advanced Breast Cancer

An Observational, Real-world Study Study of UTD1 in Chinese Advanced Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05386511

Enrollment

150

Registered

2022-05-23

Start date

2022-04-01

Completion date

2024-02-01

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Plan to receive or has received UTD1 monotherapy or UTD1 based therapy 4. Available medical history.

Exclusion criteria

1.Incomplete medical history.

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival

Secondary

Measure	Time frame	Description
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Countries

China

Outcome results